| scholarly article | Q13442814 |
| P2093 | author name string | Qing Chen | |
| Ke Zhang | |||
| Angela Coxon | |||
| Karen Rex | |||
| Jilin Sun | |||
| Xiao Feng | |||
| Teresa Burgess | |||
| Stephen Kaufman | |||
| Richard Kendall | |||
| Robert Radinsky | |||
| Susanne Meyer | |||
| Russell C Cattley | |||
| Xiao-Chi Jia | |||
| Larry Green | |||
| Gary Elliott | |||
| Luke Li | |||
| Trace Tsuruda | |||
| Jan Sun | |||
| Shu-Yin Ho | |||
| Kevin McDorman | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 1721-9 | |
| P577 | publication date | 2006-02-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors | |
| P478 | volume | 66 |
| Q38661997 | A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor Receptor |
| Q39238952 | A New Anti-c-Met Antibody Selected by a Mechanism-Based Dual-Screening Method: Therapeutic Potential in Cancer |
| Q41574359 | A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy |
| Q36777999 | A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met |
| Q38773268 | A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors |
| Q30427677 | A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma |
| Q55265062 | A review of soft-tissue sarcomas: translation of biological advances into treatment measures. |
| Q35870232 | Affinity peptide for targeted detection of dysplasia in Barrett's esophagus |
| Q30428363 | An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth |
| Q37974354 | Angiogenesis and invasion in cancer |
| Q37138521 | Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth |
| Q35205410 | Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. |
| Q37129915 | Antiangiogenic therapy in brain tumors |
| Q38214511 | Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer |
| Q46830250 | Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer |
| Q35914680 | Association of activated c‐Met with NRAS‐mutated human melanomas |
| Q26751332 | Biomarker development in MET-targeted therapy |
| Q41490164 | Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain |
| Q53221535 | Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma. |
| Q37690299 | Clinical implications of MET gene copy number in lung cancer |
| Q35159738 | Design and synthesis of 3,3'-biscoumarin-based c-Met inhibitors |
| Q50510228 | Development and characterization of a human antibody reference panel against erythropoietin suitable for the standardization of ESA immunogenicity testing |
| Q46344608 | Development of Angiotensin IV Analogs as Hepatocyte Growth Factor/Met Modifiers |
| Q34187026 | Discovery of a 5H-Benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer |
| Q39158608 | Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors |
| Q36610910 | Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion |
| Q29010479 | Drug development against metastasis-related genes and their pathways: A rationale for cancer therapy |
| Q34782774 | Drug development of MET inhibitors: targeting oncogene addiction and expedience |
| Q38839110 | Drug discovery in advanced prostate cancer: translating biology into therapy |
| Q33756853 | EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. |
| Q38019977 | Emerging New Agents for the Management of Patients with Non-Small Cell Lung Cancer |
| Q36764016 | Emerging monoclonal antibody therapies for malignant gliomas |
| Q39186427 | Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model |
| Q34127138 | Experimental approaches for the treatment of malignant gliomas |
| Q35677873 | Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression |
| Q38847534 | Expression array analysis of the hepatocyte growth factor invasive program |
| Q34013850 | Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer |
| Q40166479 | From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice |
| Q40387762 | Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. |
| Q38019410 | Growth factor signaling in metastasis: current understanding and future opportunities |
| Q34550898 | HGF rescues colorectal cancer cells from EGFR inhibition via MET activation |
| Q37158288 | HGF upregulates CXCR4 expression in gliomas via NF-kappaB: implications for glioma cell migration |
| Q39214964 | HGF–MET Cascade, a Key Target for Inhibiting Cancer Metastasis: The Impact of NK4 Discovery on Cancer Biology and Therapeutics |
| Q33607965 | Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment |
| Q41893732 | Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth |
| Q44785670 | Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. |
| Q36497083 | High-throughput mutational analysis of the human cancer genome |
| Q37028982 | Human monoclonal antibodies from transgenic mice |
| Q24645410 | Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma |
| Q43483788 | Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease |
| Q55362851 | Immunotherapies: Exploiting the Immune System for Cancer Treatment. |
| Q38310029 | Improving the oral efficacy of recombinant granulocyte colony-stimulating factor and transferrin fusion protein by spacer optimization |
| Q36730368 | In Vivo c-Met Pathway Inhibition Depletes Human Glioma Xenografts of Tumor-Propagating Stem-Like Cells |
| Q37363691 | In vivo cancer biomarkers of esophageal neoplasia |
| Q37138513 | Incomplete target neutralization by the anti-cancer antibody rilotumumab |
| Q37974368 | Inhibiting angiogenesis in malignant gliomas |
| Q37004664 | Inhibition of angiogenesis and invasion in malignant gliomas |
| Q34398276 | Inhibition of the MET Receptor Tyrosine Kinase as a Novel Therapeutic Strategy in Medulloblastoma |
| Q43167320 | Inhibitors targeting hepatocyte growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases |
| Q37052713 | Liver regeneration and tumor stimulation--a review of cytokine and angiogenic factors. |
| Q37232416 | MET as a target for treatment of chest tumors |
| Q92912403 | MET in glioma: signaling pathways and targeted therapies |
| Q38956316 | MET overexpression and gene amplification in NSCLC: a clinical perspective. |
| Q38008247 | MET: a promising anticancer therapeutic target |
| Q38089834 | Malignant glioma drug discovery – targeting protein kinases |
| Q48249128 | Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging |
| Q84806879 | Mimics of the Dimerization Domain of Hepatocyte Growth Factor Exhibit Anti-Met and Anticancer Activity |
| Q36828371 | Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy |
| Q35691515 | Molecular imaging of c-Met tyrosine kinase activity. |
| Q42151322 | Molecular therapy targeting Sonic hedgehog and hepatocyte growth factor signaling in a mouse model of medulloblastoma |
| Q36817109 | Molecularly targeted therapies for malignant gliomas: advances and challenges |
| Q37974367 | Molecularly targeted therapy in neuro-oncology |
| Q38013713 | Monoclonal Antibody Therapy For Malignant Glioma |
| Q39399346 | Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy |
| Q34236834 | Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET. |
| Q35902144 | Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells |
| Q34558669 | Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. |
| Q42276990 | Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer |
| Q38442573 | Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research |
| Q80371652 | Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys |
| Q35168185 | Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine Network |
| Q37996468 | Potential dual role of KGF/KGFR as a target option in novel therapeutic strategies for the treatment of cancers and mucosal damages |
| Q92068036 | Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma |
| Q38007133 | Progress in cancer therapy targeting c-Met signaling pathway |
| Q37763945 | Pseudo-active sites of protease domains: HGF/Met and Sonic hedgehog signaling in cancer |
| Q34293078 | Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102 |
| Q50985091 | Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment |
| Q37024839 | Recent discoveries in the genetics of melanoma and their therapeutic implications |
| Q89604993 | Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion |
| Q42693879 | Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial |
| Q37952015 | Role of MetMAb (OA-5D5) in c-MET active lung malignancies |
| Q38167258 | Role of met axis in head and neck cancer |
| Q37730020 | Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers |
| Q38028939 | Significance of regenerating islet-derived type IV gene expression in gastroenterological cancers |
| Q40004623 | Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma |
| Q35116206 | Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors |
| Q37779571 | Structural and mechanistic insight into how antibodies inhibit serine proteases. |
| Q59129187 | Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors |
| Q35737325 | Targetable "driver" mutations in non small cell lung cancer. |
| Q38074430 | Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? |
| Q39098665 | Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor. |
| Q38757070 | Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer |
| Q37013777 | Targeting the HGF/Met signaling pathway in cancer therapy |
| Q36142604 | Targeting the HGF/Met signalling pathway in cancer. |
| Q37792116 | Targeting the MET oncogene in cancer and metastases. |
| Q37331862 | Targeting the Met signaling pathway in renal cancer. |
| Q27011423 | Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling |
| Q38216590 | Targeting the oncogenic Met receptor by antibodies and gene therapy |
| Q35740444 | The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy |
| Q38239580 | The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms? |
| Q34141913 | The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer |
| Q41954928 | The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth |
| Q37621003 | The function, proteolytic processing, and histopathology of Met in cancer |
| Q81029090 | The importance of histology and cytogenetics in decision making for renal cell carcinoma |
| Q37165851 | The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases |
| Q37773788 | The role of signaling pathways in the development and treatment of hepatocellular carcinoma |
| Q33426563 | Therapeutic strategies for inhibiting invasion in glioblastoma |
| Q36915616 | Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis |
| Q30436756 | Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor |
| Q39983091 | Transcriptional regulation of the hepatocyte growth factor gene by pyrrolidine dithiocarbamate |
| Q36643703 | Treatment outcome for metastatic papillary renal cell carcinoma patients |
| Q54942652 | Trends in Malignant Glioma Monoclonal Antibody Therapy. |
| Q41660598 | Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain. |
| Q37765586 | Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy |
| Q27649203 | c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations |
| Q37169357 | c-Met targeted therapy of cholangiocarcinoma |
Search more.